The phase 1 SARC025 study (NCT02044120) of the PARP1/2 inhibitor niraparib (Zejula) in combination with either temozolomide (Temodar) or irinotecan in patients with pretreated Ewing sarcoma (ES) suggested that either combination was tolerable when dose adjustments were made.
Based on these findings, SARC025 study has commenced a triple-combination study of niraparib plus temozolomide and irinotecan in this patient population.
“On the basis of preclinical data suggesting maximum synergy with the 3 agents, we hypothesize that with lower doses of all 3 agents, there may be less hematologic and gastrointestinal toxicity with the potential for synergistic efficacy,” noted the study authors who were led by Rashmi Chugh, MD. “However, whether this will offer any advantage over higher dose, standard temozolomide and irinotecan therapy remains to be determined.”
Patients enrolled in arm…
